{"answer":{"query":"Victoza 3-Pak","resolved_as":"applications","packages":9,"applications":["NDA022341"],"identity":{"application_numbers":["NDA022341"],"marketing_categories":["NDA","NDA AUTHORIZED GENERIC"],"labelers":[{"text":"NOVO NORDISK, INC.","untrusted":true},{"text":"Teva Pharmaceuticals, Inc.","untrusted":true}],"dosage_forms":[{"text":"INJECTION","untrusted":true}],"marketing_start":{"earliest":"2010-01-25","latest":"2025-01-27","packages_with_a_start_date":9}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":9,"negotiated_price_ends":null,"rows":[{"ndc":"00169406012","name":{"text":"VICTOZA 6MG/ML 2X3ML","untrusted":true},"class":"B","nadac_per_unit":87.75645,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00169406013","name":{"text":"VICTOZA 6MG/ML 3X3ML","untrusted":true},"class":"B","nadac_per_unit":87.75209,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00169406090","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00169406099","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00480366720","name":{"text":"LIRAGLUTIDE REC INJ 6MG/ML3MLX2","untrusted":true},"class":"G","nadac_per_unit":28.58316,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00480366722","name":{"text":"LIRAGLUTIDE REC INJ 6MG/ML3MLX3","untrusted":true},"class":"G","nadac_per_unit":29.18733,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"50090285300","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"50090450300","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"50090750100","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"generic_entry":[{"application":"NDA022341","date":"2037-07-09","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"9968659*PED","productNo":"001"},"latest_patent_expiry":"2037-07-09","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":4,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":2,"exclusivities_listed":0,"fact_id":"4c9d0a2e7173184a8ed76b3b"}],"label_history":{"events_total":28,"non_cmc_events":27,"counts_by_class":{"LABELING":17,"EFFICACY":6,"REMS":4},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA022341","submission_no":46,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-14","documents":[{"type":"Letter","date":"2025-10-15","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022341Orig1s046ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-10-15","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf","untrusted":true}}],"fact_id":"22c258e16bb843d4613e6cae"},{"application":"NDA022341","submission_no":44,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-05-28","documents":[{"type":"Label","date":"2025-05-30","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf","untrusted":true}}],"fact_id":"e5304df709cee382c9642cea"},{"application":"NDA022341","submission_no":42,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-02-12","documents":[{"type":"Letter","date":"2025-02-13","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022341Orig1s042ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-02-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341Orig1s042lbl.pdf","untrusted":true}}],"fact_id":"6b78f7178d87c61542d8d054"},{"application":"NDA022341","submission_no":43,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-11-01","documents":[{"type":"Label","date":"2024-11-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022341Orig1s043lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-11-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022341Orig1s043ltr.pdf","untrusted":true}}],"fact_id":"2f0de317220201062d8ff67f"},{"application":"NDA022341","submission_no":39,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-07-05","documents":[{"type":"Label","date":"2023-07-06","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-07-07","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/022341Orig1s039ltr.pdf","untrusted":true}}],"fact_id":"8094357c14d4ce9de3a93285"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"AP1":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA022341","product_no":"001","te_code":"AP1","marketing_status":"Prescription","drug_name":{"text":"VICTOZA","untrusted":true},"form":{"text":"SOLUTION;SUBCUTANEOUS","untrusted":true},"strength":{"text":"18MG/3ML (6MG/ML)","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":9,"most_recent":[{"recall_number":"D-0622-2021","classification":"Class II","status":"Terminated","report_date":"2021-04-21","recall_initiated":"2021-03-22","recalling_firm":{"text":"Novo Nordisk Inc","untrusted":true},"reason":{"text":"Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.","untrusted":true},"packages_named":4,"fact_id":"debc5dbf3bd45a4da2d4a184"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"supply":{"fda_shortage_status_counts":{"Current":4},"packages_with_a_termination_date":0,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"spending":{"reported_under":{"generic":{"text":"Liraglutide","untrusted":true},"brand":{"text":"Victoza 3-Pak","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1545815414.8,"claims":1040550,"beneficiaries":224779,"average_spending_per_claim_usd":1485.575335,"fact_id":"302b385873c87d6b6f27f7a9"},{"year":2021,"gross_spending_usd":1422292583.1,"claims":884941,"beneficiaries":200512,"average_spending_per_claim_usd":1607.2174112,"fact_id":"b5e49a58f1095b0115333e58"},{"year":2022,"gross_spending_usd":1238594872.4,"claims":724049,"beneficiaries":167181,"average_spending_per_claim_usd":1710.6506223,"fact_id":"cebd5d0c97f4c8916c6bdbd7"},{"year":2023,"gross_spending_usd":1004635145.2,"claims":574218,"beneficiaries":142213,"average_spending_per_claim_usd":1749.5709734,"fact_id":"f48f4ea459317fc51eca0875"},{"year":2024,"gross_spending_usd":203063050.37,"claims":181068,"beneficiaries":62754,"average_spending_per_claim_usd":1121.4739787,"fact_id":"b4b543ca679f7bfc1644be64"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"rems":{"programs":[{"application":"NDA022341","program":{"text":"Victoza","untrusted":true},"rems_id":"66","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2010-01-25","last_modified":"2017-07-26","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=66","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"05f7e848e82f2f49f498a881"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"medicaid_state_utilization":{"year":2025,"states_with_data":39,"all_states_medicaid_reimbursed_usd":41465774.73,"all_states_medicaid_paid_prescriptions":96239,"top_states":[{"state":"WA","medicaid_paid_prescriptions":22034,"medicaid_reimbursed_usd":9229163.68,"total_reimbursed_usd":9296691.15,"packages":2,"covers":"all_record_types","fact_id":"976261a4d31dcfa8398acc48"},{"state":"NJ","medicaid_paid_prescriptions":16453,"medicaid_reimbursed_usd":7259680.66,"total_reimbursed_usd":7277002.61,"packages":2,"covers":"fee_for_service_only","fact_id":"313f1aae439cc83a9068de8e"},{"state":"IL","medicaid_paid_prescriptions":10492,"medicaid_reimbursed_usd":5181693.04,"total_reimbursed_usd":5198822.34,"packages":2,"covers":"all_record_types","fact_id":"128773992046f7c96f777d6d"},{"state":"CA","medicaid_paid_prescriptions":9294,"medicaid_reimbursed_usd":3674030.25,"total_reimbursed_usd":3957226.44,"packages":2,"covers":"fee_for_service_only","fact_id":"3075e18c65d5e071c1637add"},{"state":"GA","medicaid_paid_prescriptions":5997,"medicaid_reimbursed_usd":2316671.9,"total_reimbursed_usd":2327280.87,"packages":2,"covers":"all_record_types","fact_id":"6f31378740b224043448b478"},{"state":"OR","medicaid_paid_prescriptions":3712,"medicaid_reimbursed_usd":1518478.18,"total_reimbursed_usd":1528081.25,"packages":2,"covers":"fee_for_service_only","fact_id":"80608b763725f5b03f040572"},{"state":"MN","medicaid_paid_prescriptions":2316,"medicaid_reimbursed_usd":1113678.26,"total_reimbursed_usd":1113678.26,"packages":2,"covers":"fee_for_service_only","fact_id":"6e82e90e3c033051db480b47"},{"state":"NY","medicaid_paid_prescriptions":1804,"medicaid_reimbursed_usd":1090476.27,"total_reimbursed_usd":1094825.4,"packages":2,"covers":"fee_for_service_only","fact_id":"9b222e3396c6655cf5edb6b1"},{"state":"CO","medicaid_paid_prescriptions":2658,"medicaid_reimbursed_usd":1070249.64,"total_reimbursed_usd":1074010.86,"packages":2,"covers":"fee_for_service_only","fact_id":"b8e36182c10c418d11aab7fc"},{"state":"AR","medicaid_paid_prescriptions":2003,"medicaid_reimbursed_usd":990589.37,"total_reimbursed_usd":990784.07,"packages":2,"covers":"fee_for_service_only","fact_id":"47c3d82c448ca9f91d540e6f"}],"unlabelled_state_code_xx":{"medicaid_paid_prescriptions":99655,"medicaid_reimbursed_usd":42921701.56,"note":"the source uses the code XX without defining it; it is reported here and never added to a state"},"built_from_facts":70,"facts_fee_for_service_only":39,"older_year_facts_not_used":95,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"61aef9249b16f5affa6d8fef","field":"ndc.listing","entity":"ndc:00169406012"},{"fact_id":"1af28a8f1a240407476476f4","field":"ndc.listing","entity":"ndc:00169406013"},{"fact_id":"2c5eb269105cac5ff1cf1d5e","field":"ndc.listing","entity":"ndc:00169406090"},{"fact_id":"4c9d0a2e7173184a8ed76b3b","field":"drug.generic_entry_earliest","entity":"application:NDA022341"},{"fact_id":"83be8f19ddec29e852ba567b","field":"drug.patent","entity":"application:NDA022341"},{"fact_id":"22c258e16bb843d4613e6cae","field":"drug.label_event","entity":"application:NDA022341"},{"fact_id":"e5304df709cee382c9642cea","field":"drug.label_event","entity":"application:NDA022341"},{"fact_id":"6b78f7178d87c61542d8d054","field":"drug.label_event","entity":"application:NDA022341"},{"fact_id":"2f0de317220201062d8ff67f","field":"drug.label_event","entity":"application:NDA022341"},{"fact_id":"8094357c14d4ce9de3a93285","field":"drug.label_event","entity":"application:NDA022341"},{"fact_id":"7b1b0a98b9054a6c93b31315","field":"drug.te_code","entity":"application:NDA022341"},{"fact_id":"f2e136b94c77ac1012192290","field":"drug.marketing_status","entity":"application:NDA022341"},{"fact_id":"debc5dbf3bd45a4da2d4a184","field":"ndc.recall","entity":"ndc:00169406013"},{"fact_id":"e687652c00b1d7e6367dc4a3","field":"ndc.shortage_row","entity":"ndc:00169406012"},{"fact_id":"4f9a1d1e1179b1ab7be0dff5","field":"ndc.shortage_row","entity":"ndc:00169406013"},{"fact_id":"2a15df6ba3ea3a8798398a76","field":"ndc.shortage_row","entity":"ndc:00480366720"},{"fact_id":"302b385873c87d6b6f27f7a9","field":"drug.partd_spending","entity":"drug:liraglutide|victoza-3-pak"},{"fact_id":"b5e49a58f1095b0115333e58","field":"drug.partd_spending","entity":"drug:liraglutide|victoza-3-pak"},{"fact_id":"cebd5d0c97f4c8916c6bdbd7","field":"drug.partd_spending","entity":"drug:liraglutide|victoza-3-pak"},{"fact_id":"f48f4ea459317fc51eca0875","field":"drug.partd_spending","entity":"drug:liraglutide|victoza-3-pak"},{"fact_id":"b4b543ca679f7bfc1644be64","field":"drug.partd_spending","entity":"drug:liraglutide|victoza-3-pak"},{"fact_id":"05f7e848e82f2f49f498a881","field":"drug.rems","entity":"application:NDA022341"},{"fact_id":"976261a4d31dcfa8398acc48","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:WA"},{"fact_id":"313f1aae439cc83a9068de8e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:NJ"},{"fact_id":"128773992046f7c96f777d6d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:IL"},{"fact_id":"3075e18c65d5e071c1637add","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366720:CA"},{"fact_id":"6f31378740b224043448b478","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:GA"},{"fact_id":"80608b763725f5b03f040572","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:OR"},{"fact_id":"6e82e90e3c033051db480b47","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:MN"},{"fact_id":"9b222e3396c6655cf5edb6b1","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:NY"},{"fact_id":"b8e36182c10c418d11aab7fc","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:CO"},{"fact_id":"47c3d82c448ca9f91d540e6f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00480366722:AR"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"trials","reason":"no ClinicalTrials.gov record set for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"AMBIGUOUS","field":"spending","reason":"2 brand and generic name pairs match; the series shown is the one with the newest year and the largest spending"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}